GNPX biotech catalysts & pipeline

GENPREX INC · Data as of 2026-09-08

Upcoming catalysts

REQORSA® Gene Therapy (generic name: quaratusugene ozeplasmid) — Interim data

H2 2026

We expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study in the first half of 2026 and expect the interim analysis in the second half of 2026.

Source filing

REQORSA and Tecentriq — Interim data

Late 2026

We expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study by the end of 2026 and expect the interim analysis in the first half of 2027.

Source filing

REQORSA and Tecentriq — Interim data

H1 2027

We expect to complete enrollment of the first 25 patients for interim analysis in the Phase 2 expansion portion of the study by the end of 2026 and expect the interim analysis in the first half of 2027.

Source filing

Explore the free biotech catalyst calendar